Tarsus Pharmaceuticals (TARS) Profit After Tax (2019 - 2026)

Tarsus Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$7.0 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 72.27% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$48.3 million (up 54.01% YoY), while the FY2025 annual figure was -$66.4 million, up 42.52% from the prior year.
• Profit After Tax was -$7.0 million for Q1 2026 at Tarsus Pharmaceuticals, up from -$8.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$5.7 million in Q2 2022 to a low of -$41.9 million in Q4 2023.
• Historically, Profit After Tax has averaged -$22.8 million across 5 years, with a median of -$23.1 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax slumped 447.17% in 2023, then soared 72.27% in 2026.
• A 5-year view of Profit After Tax shows it stood at -$13.6 million in 2022, then plunged by 208.13% to -$41.9 million in 2023, then surged by 44.84% to -$23.1 million in 2024, then soared by 63.77% to -$8.4 million in 2025, then grew by 16.79% to -$7.0 million in 2026.
• The last three Profit After Tax figures came in at -$7.0 million (Q1 2026), -$8.4 million (Q4 2025), and -$12.6 million (Q3 2025), per Business Quant data.